The scope of human genetic diversity is forcing drug makers to examine more closely the molecular mechanisms behind complex disease and drug response.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Conceptual and terminological confusion around personalised medicine: a coping strategy
BMC Medical Ethics Open Access 18 July 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Motulsky, A. 1957. Drug reactions, enzymes, and biochemical genetics. J. Am. Med. Assoc. 165: 835–837.
Katow, W. 1962. Pharrnacogenetics—Heredity and the Responses to Drugs. W.B. Saunders. Philadelphia
Vessell, E.S. Page, J.G. and Passanti, T.G. 1971. Genetic and environmental factors affecting ethanol metabolism, Clin. Pharmacol. Ther. 12: 192–201.
Weber, W.W. 1997. Pharmacogenetics. Oxford University Press. New York.
Lichter, J. and McNamara, D. 1995. What's in a gene: using genetic information for the design of clinical trials. Curr. Opin. Biotechnol. 6: 715–717.
Meyer, U.A. 1997. Medically relevant genetic variation of drug effects.Evolution in Health and Disease. Oxford University Press, Oxford. UK. In press.
Rights and permissions
About this article
Cite this article
Marshall, A. Laying the foundations for personalized medicines. Nat Biotechnol 15, 954–957 (1997). https://doi.org/10.1038/nbt1097-954
Issue Date:
DOI: https://doi.org/10.1038/nbt1097-954
This article is cited by
-
Conceptual and terminological confusion around personalised medicine: a coping strategy
BMC Medical Ethics (2016)
-
Medizinische Prädiktion, Prävention und Gerechtigkeit: Anmerkungen zu ethischen Dimensionen eines biomedizinischen Ideals
Ethik in der Medizin (2010)
-
A regulatory protocol for pharmacogenomics services
The Pharmacogenomics Journal (2002)
-
Review of “angiotensin genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II”
Current Hypertension Reports (1999)
-
Pharmacogenomics: Will the regulators approve?
Nature Biotechnology (1998)